|
|
|
|
|
|
|
|
|
|
US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology
US firm corners exclusive license for RAD51C cancer gene
"Already facing a legal challenge to its BRCA1 and BRCA2 patents,
Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive
licence for another breast and ovarian cancer-associated gene, RAD51C ,
under agreement with the German Consortium for Hereditary Breast and
Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.
“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.